

Kriya Medical receives ICMR approval for new kit to detect influenza

17 March 2023 | News

The RT-qPCR kit can detect the presence or absence of three pathogens - Influenza, SARS CoV2, and Respiratory Syncytial Virus (RSV)



KRIVIDA TRIVUS, developed by Chennai-based KRIYA Medical Technologies, has received approval from the Indian Council of Medical Research (ICMR). The RT-qPCR kit can detect the presence or absence of three pathogens - Influenza (H1N1, H3N2, Yamagata and Victoria sublineages), SARS CoV2, and Respiratory Syncytial Virus (RSV).

The three pathogens have similar initial symptoms but differ in how the illness progresses, how easily they spread, and how they are treated. The kit helps identify which pathogen is causing the respiratory illness, aiding clinicians and patients to opt for the right course of treatment.

The kit can help healthcare providers stay informed about the current burden of respiratory infections and be prepared for any new ones that may emerge. The kit has the shortest cycle time of 27 minutes. The time taken for result to be read can vary between 50-60 minute.

It's an open kit that can be used in all the available RT PCR equipment. The kit is evaluated by ICMR at National Institute of Virology, Pune, using 225 known positive samples and 85 negative samples. The overall sensitivity of KRIVIDA TRIVUS is 99.11% and specificity is 100%.

The kit will be produced at KRIYA's state-of-the-art manufacturing facility in Oragadam in Chennai. The test is priced competitively, and it will soon be commercially available across the country.